Loading organizations...
Based in Menlo Park, California, Adaptyx Biosciences is a biotechnology company developing minimally invasive biowearable devices for the continuous, real-time monitoring of multiple small molecules and proteins. The company utilizes an artificial intelligence-driven molecular switch platform to create biosensors that track biomarkers for clinical applications in heart failure, kidney function, and personalized medicine. Built upon 17 years of academic research, the pre-revenue firm is currently pursuing FDA clearance for its initial clinical monitoring systems. Adaptyx Biosciences has raised $23 million in total venture funding to date, including a recent $14 million seed round backed by investors such as Interlagos, Overwater Ventures, and Stanford University. The core technology originated from laboratories at the Chan Zuckerberg Biohub before the enterprise was officially founded in 2022 by Vijit Sabnis, Alex Yoshikawa, H. Tom Soh, and Joe DeSimone.
Adaptyx Biosciences has raised $14.0M across 1 funding round.
Adaptyx Biosciences has raised $14.0M in total across 1 funding round.
Adaptyx Biosciences has raised $14.0M across 1 funding round. Most recently, it raised $14.0M Seed in October 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Oct 1, 2025 | $14M Seed | Achal Upadhyaya | ARCH Venture Partners, Atomic, Coatue, Future Ventures, Insight Partners, Overwater Ventures, RA Capital, TWO Sigma Ventures, Anne Wojcicki, Cantos, Chan Zuckerberg Biohub, Humba Ventures, Hyperlink Ventures, Seaside Ventures, Stanford University, Starbloom Capital | Announced |
Adaptyx Biosciences has raised $14.0M in total across 1 funding round.
Adaptyx Biosciences's investors include Achal Upadhyaya, ARCH Venture Partners, Atomic, Coatue, Future Ventures, Insight Partners, Overwater Ventures, RA Capital, Two Sigma Ventures, Anne Wojcicki, Cantos, Chan Zuckerberg Biohub.
Adaptyx Biosciences is a biotech startup developing a programmable biowearable patch for continuous, multi-analyte molecular monitoring using synthetic DNA-based molecular switches.[1][2] The patch analyzes interstitial fluid to track biomarkers like hormones, glucose, drugs, electrolytes, and proteins in real-time, streaming data to AI algorithms for clinician dashboards and insights that enable earlier interventions in clinical settings and everyday health.[1][2][3] It targets patients with conditions like heart failure, reducing hospital readmissions by detecting issues weeks early, and serves clinicians, hospitals, and consumers by replacing lab draws and clinic visits with always-on monitoring.[2][5] Founded in 2022 in Menlo Park, CA, the company has raised $23M in funding, completed human feasibility studies, validated 12+ analytes, and is pursuing FDA clearance while showing strong growth via investor backing and Stanford-licensed patents.[1][2][3]
Adaptyx emerged from 17 years of Stanford-led research, with co-founders—including CEO Vig—who collaborated there to address the lack of continuous biochemical data in healthcare.[2][5] The idea crystallized around synthetic DNA molecular switches, resulting in 25 patent applications (9 families exclusively licensed from Stanford) after cracking real-time biomarker tracking.[2][5] Pivotal early traction includes validating 12+ analytes, launching human feasibility studies, and securing $23M total funding since 2022, highlighted by a $14M seed round in 2025 led by Interlagos with participation from Overwater Ventures, Starbloom Capital, Stanford University, Chan Zuckerberg Biohub, and others.[1][3] This momentum stems from a mission to prevent complications like heart failure readmissions, humanizing their drive: "Every patient deserves to see their next birthday."[5]
Adaptyx rides the convergence of wearables, synthetic biology, and AI-driven precision medicine, shifting healthcare from episodic snapshots (lab draws, check-ins) to continuous streams amid rising chronic disease burdens like heart failure affecting 8M patients.[2][5] Timing aligns with post-glucose-monitor maturity, where multi-analyte needs (hormones, drugs) demand scalable biosensors; market forces like AI analytics growth and FDA wearable approvals favor rapid scaling.[1][3] It influences the ecosystem by licensing Stanford IP, attracting top VCs (e.g., Chan Zuckerberg Biohub), and enabling "always-on" care that cuts costs/readmissions, paving the way for personalized therapies in wellness and narrow-index drugs.[2][3]
Adaptyx is poised for FDA clearance milestones, expanding from clinical (heart failure, acute therapies) to consumer wellness with more analytes and AI refinements.[1][2] Trends like AI-optimized biosensors and interstitial fluid tech will accelerate adoption, potentially dominating multi-analyte monitoring as funding fuels commercialization.[3] Its influence may evolve into a platform leader, licensing switches or partnering with pharma for drug monitoring, ultimately redefining proactive healthcare from reactive patches to ecosystem-wide intelligence—delivering the continuous data that saves lives, as their founders envisioned.[5]
